Discussion about this post

User's avatar
James Emanuel's avatar

Fairfax India Update

The principal “problem child” in the portfolio, as identified in the earlier analysis, was Sanmar Chemical Enterprises Ltd. That overhang has now been removed: in April 2026, Fairfax India announced the sale of its entire equity interest in SCEL for INR 2,480 million (approximately US$27 million), leaving the company with no remaining economic exposure to the asset.

This is a clear positive for shareholders. SCEL had been a persistent drag on reported performance through repeated valuation markdowns, including a material fair value decline recorded in Fairfax India’s 2025 results. Its disposal simplifies the portfolio and eliminates the only meaningful legacy holding that had consistently detracted from net asset value progression.

Attention now shifts to Bengaluru International Airport Ltd. (BIAL), which represents the dominant component of Fairfax India’s underlying value. A partial monetization of that stake later in 2026 would be strategically important: it could establish a transparent market benchmark for the remaining holding while also generating liquidity for debt reduction, share buybacks, or redeployment into new investments.

Such an event could prove to be a major catalyst for rerating the shares. Fairfax India continues to trade at a substantial discount to intrinsic value, due in large part to the market’s skepticism toward private asset marks and the fact that several fast-appreciating assets remain carried at valuations close to cost or otherwise at conservative levels relative to likely market values.

James Emanuel's avatar

Since the market fails to grasp the true value of it's portfolio, Fairfax India has now launched it's own podcast which explores each of its holding companies in turn: https://www.fairfaxindia.ca/podcast/ first episode is BIAL. Worth a listen! 😉

10 more comments...

No posts

Ready for more?